Wallachbeth Capital宣布,bioAffinity Technologies已成功完成180万美元的注册直接融资交易,本次融资以普通股形式进行,定价遵循纳斯达克市场规则,采用市场价格定价机制。
Wallachbeth Capital宣布,bioAffinity Technologies已成功完成180万美元的注册直接融资交易,本次融资以普通股形式进行,定价遵循纳斯达克市场规则,采用市场价格定价机制。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.